Metabolic reprogramming and drug resistance in hepatocellular carcinoma: The emerging role of SREBP2-driven cholesterol metabolism.
Hepatocellular carcinoma (HCC) is the most common cancer and a leading cause of death. Multi-kinase inhibitors are vital for treating advanced HCC, yet drug resistance remains a major challenge. The molecular basis of metabolic adaptation to drug resistance is poorly understood. Evidence indicates that metabolic reprog...